BioCryst Pharmaceuticals, Inc. (BCRX)
Develops oral and injected medicines for rare diseases like hereditary angioedema and influenza.
$9.74+0.02%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+22.5%
The outlook
BCRX trades at $9.74, positioned well above its 50- and 200-day moving averages and roughly 72% of the way up its 52-week range. Analysts overwhelmingly favor the stock with a Strong Buy consensus, and the average price target sits around 116% above the current price. The overall technical and sentiment backdrop leans decidedly bullish.
What’s behind the score
Analyst consensusStrong Buy — 1.5 avg of 11 analysts
Price trendAbove its 50- & 200-day averages
52-week range72% of the way from its 52-week low to high
Price targetAvg target +116% vs current price
Analyst price target
~12-month · 11 analysts$21.00average target+115.6% vs now
Now $9.74
Low $12.00High $32.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$2.48B
52-wk high
$11.22
52-wk low
$6.00
50-day avg
$9.24
200-day avg
$8.19
Trailing P/E
—